

Contents

Highlights of This Issue 1

SPECIAL FEATURES

CCR Translations

- 3 | **The Importance of Doing Trials Right While Doing the Right Trials**
David M. Dilts and Steven K. Cheng
See article p. 256
- 6 | **Elusive Extranuclear Estrogen Receptors in Breast Cancer**
Ellis R. Levin
See article p. 118

CCR Drug Updates

- 9 | **Vemurafenib and BRAF Inhibition: A New Class of Treatment for Metastatic Melanoma**
Jason J. Luke and F. Stephen Hodi

Molecular Pathways

- 15 | **Molecular Pathways: Targeting Proteasomal Protein Degradation in Cancer**
Susan M. Molineaux

CCR Focus

- 22 | **On Drug Development, Chance, and the Prepared Mind**
Susan E. Bates
- 23 | **Drug Development: Portals of Discovery**
Susan E. Bates, Laleh Amiri-Kordestani, and Giuseppe Giaccone
- 33 | **BRAF Inhibitors for the Treatment of Metastatic Melanoma: Clinical Trials and Mechanisms of Resistance**
Alexander Marzuka Alcalá and Keith T. Flaherty
- 40 | **The Insulin Receptor/Insulin-Like Growth Factor Receptor Family as a Therapeutic Target in Oncology**
Michael Pollak
- 51 | **Inhibitors Targeting Mitosis: Tales of How Great Drugs against a Promising Target Were Brought Down by a Flawed Rationale**
Edina Komlodi-Pasztor, Dan L. Sackett, and Antonio Tito Fojo

- 64 | **Hsp90 Molecular Chaperone Inhibitors: Are We There Yet?**
Len Neckers and Paul Workman

HUMAN CANCER BIOLOGY

- 77 | **Polycomb Repressor Complex-2 Is a Novel Target for Mesothelioma Therapy**
Clinton D. Kemp, Mahadev Rao, Sichuan Xi, Suzanne Inchauste, Hareesh Mani, Patricia Fetsch, Armando Filie, Mary Zhang, Julie A. Hong, Robert L. Walker, Yuelin J. Zhu, R. Taylor Ripley, Aarti Mathur, Fang Liu, Maocheng Yang, Paul A. Meltzer, Victor E. Marquez, Assunta De Rienzo, Raphael Bueno, and David S. Schrupp
- 91 | **Eph-B2/Ephrin-B2 Interaction Plays a Major Role in the Adhesion and Proliferation of Waldenstrom's Macroglobulinemia**
Feda Azab, Abdel Kareem Azab, Patricia Maiso, Teresa Calimeri, Ludmila Flores, Yang Liu, Phong Quang, Aldo M. Roccaro, Antonio Sacco, Hai T. Ngo, Yong Zhang, Brittany L. Morgan, Ruben D. Carrasco, and Irene M. Ghobrial
- 105 | **Costimulatory Protein 41gB7H3 Drives the Malignant Phenotype of Glioblastoma by Mediating Immune Escape and Invasiveness**
Dieter Lemke, Philipp-Niclas Pfenning, Felix Sahm, Ann-Catherine Klein, Tore Kempf, Uwe Warnken, Martina Schnölzer, Ruxandra Tudoran, Michael Weller, Michael Platten, and Wolfgang Wick
- 118 | **Cytoplasmic Estrogen Receptor in Breast Cancer**
Allison W. Welsh, Donald R. Lannin, Gregory S. Young, Mark E. Sherman, Jonine D. Figueroa, N. Lynn Henry, Lisa Ryden, Chungyeul Kim, Richard R. Love, Rachel Schiff, and David L. Rimm
See commentary p. 6

CANCER THERAPY: PRECLINICAL

- 127 | **STAT5A-Mediated SOCS2 Expression Regulates Jak2 and STAT3 Activity Following c-Src Inhibition in Head and Neck Squamous Carcinoma**
Banibrata Sen, Shaohua Peng, Denise M. Woods, Ignacio Wistuba, Diana Bell, Adel K. El-Naggar, Stephen Y. Lai, and Faye M. Johnson

- 140 **Phenylarsine Oxide Induces Apoptosis in Bax- and Bak-Deficient Cells through Upregulation of Bim**
Biyun Ni, Qi Ma, Baowei Li, Lixia Zhao, Yong Liu, Yushan Zhu, and Quan Chen
- 152 **Synergistic Antitumor Activity of Anti-CD25 Recombinant Immunotoxin LMB-2 with Chemotherapy**
Rajat Singh, Yujian Zhang, Ira Pastan, and Robert J. Kreitman
- 161 **Modulation of the Tumor Microvasculature by Phosphoinositide-3 Kinase Inhibition Increases Doxorubicin Delivery *In Vivo***
Naseer Qayum, Jaehong Im, Michael R. Stratford, Eric J. Bernhard, W. Gillies McKenna, and Ruth J. Muschel
- 170 **Modeling the Transcriptional Consequences of Epidermal Growth Factor Receptor Ablation in Ras-Initiated Squamous Cancer**
Lisa Nolan Wright, Andrew Ryscavage, Glenn Merlino, and Stuart H. Yuspa
- 184 **Antitumor Activity of NVP-BKM120—A Selective Pan Class I PI3 Kinase Inhibitor Showed Differential Forms of Cell Death Based on p53 Status of Glioma Cells**
Dimpy Koul, Jun Fu, Ruijun Shen, Tiffany A. LaFortune, Shuzhen Wang, Ningyi Tiao, Yong-Wan Kim, Juinn-Lin Liu, Deepti Ramnarian, Ying Yuan, Carlos Garcia-Echeverria, Sauveur-Michel Maira, and W.K. Alfred Yung

IMAGING, DIAGNOSIS, PROGNOSIS

- 196 **Validation of Genetic Sequence Variants as Prognostic Factors in Early-Stage Head and Neck Squamous Cell Cancer Survival**
Abul Kalam Azad, Isabelle Bairati, Elodie Samson, Dangxiao Cheng, Maryam Mirshams, Xin Qiu, Sevtap Savas, John Waldron, Changshu Wang, David Goldstein, Wei Xu, Francois Meyer, and Geoffrey Liu
- 207 **Noninvasive Detection of Breast Cancer Lymph Node Metastasis Using Carbonic Anhydrases IX and XII Targeted Imaging Probes**
Narges K. Tafreshi, Marilyn M. Bui, Kelsey Bishop, Mark C. Lloyd, Steven A. Enkemann, Alexis S. Lopez, Dominique Abrahams, Bradford W. Carter, Josef Vagner, Stephen R. Grobmyer, Robert J. Gillies, and David L. Morse

- 220 **Early [¹⁸F]Fluorodeoxyglucose Positron Emission Tomography at Two Days of Gefitinib Treatment Predicts Clinical Outcome in Patients with Adenocarcinoma of the Lung**
Ryo Takahashi, Haruhiko Hirata, Isao Tachibana, Eku Shimosegawa, Atsuo Inoue, Izumi Nagatomo, Yoshito Takeda, Hiroshi Kida, Sho Goya, Takashi Kijima, Mitsuhiro Yoshida, Toru Kumagai, Atsushi Kumanogoh, Meinoshin Okumura, Jun Hatazawa, and Ichiro Kawase
- 229 **Lymphatic Invasion Is Independently Prognostic of Metastasis in Primary Cutaneous Melanoma**
Xiaowei Xu, Lianjun Chen, DuPont Guerry, Peter R. Dawson, Wei-ting Hwang, Patricia VanBelle, David E. Elder, Paul J. Zhang, Michael E. Ming, Lynn Schuchter, and Phyllis A. Gimotty
- 238 ***In Vivo* Positron Emission Tomography Imaging of Protease Activity by Generation of a Hydrophobic Product from a Noninhibitory Protease Substrate**
Chih-Hung Chuang, Kuo-Hsiang Chuang, Hsin-Ell Wang, Steve R. Roffler, Jen-taie Shiea, Shey-Cherng Tzou, Ta-Chun Cheng, Chien-Han Kao, Shih-Yen Wu, Wei-Lung Tseng, Chiu-Min Cheng, Ming-Feng Hou, Ju-Ming Wang, and Tian-Lu Cheng

CANCER THERAPY: CLINICAL

- 248 **A Phase I Weekly Dosing Study of Brentuximab Vedotin in Patients with Relapsed/Refractory CD30-Positive Hematologic Malignancies**
Michelle A. Fanale, Andres Forero-Torres, Joseph D. Rosenblatt, Ranjana H. Advani, Anna R. Franklin, Dana A. Kennedy, Tae H. Han, Eric L. Sievers, and Nancy L. Bartlett
- 256 **Achieving Sufficient Accrual to Address the Primary Endpoint in Phase III Clinical Trials from U.S. Cooperative Oncology Groups**
Anneke T. Schroen, Gina R. Petroni, Hongkun Wang, Monika J. Thielen, Robert Gray, Jacqueline Benedetti, Xiaofei F. Wang, Daniel J. Sargent, Donald L. Wickerham, Walter Cronin, Benjamin Djulbegovic, and Craig L. Slingluff Jr
See commentary p. 3

263 **Skin Tumors Induced by Sorafenib; Paradoxical RAS–RAF Pathway Activation and Oncogenic Mutations of *HRAS*, *TP53*, and *TGFBR1***

Jean Philippe Arnault, Christine Mateus, Bernard Escudier, Gorana Tomasic, Janine Wechsler, Emilie Hollville, Jean-Charles Soria, David Malka, Alain Sarasin, Magalie Larcher, Jocelyne André, Nyam Kamsu-Kom, Lise Boussemart, Ludovic Lacroix, Alain Spatz, Alexander M. Eggermont, Sabine Druillennec, Stephan Vagner, Alain Eychène, Nicolas Dumaz, and Caroline Robert

273 **Concurrent Temozolomide and Dose-Escalated Intensity-Modulated Radiation Therapy in Newly Diagnosed Glioblastoma**

Christina I. Tsien, Doris Brown, Daniel Normolle, Matthew Schipper, Morand Piert, Larry Junck, Jason Heth, Diana Gomez-Hassan, Randall K. Ten Haken, Thomas Chenevert, Yue Cao, and Theodore Lawrence

PREDICTIVE BIOMARKERS AND PERSONALIZED MEDICINE

280 **Molecular Determinants of Retinoic Acid Sensitivity in Pancreatic Cancer**

Sonal Gupta, Dipankar Pramanik, Radha Mukherjee, Nathaniel R. Campbell, Sathyanarayanan Elumalai, Roeland F. de Wilde, Seung-Mo Hong, Michael G. Goggins, Ana De Jesus-Acosta, Daniel Laheru, and Anirban Maitra

290 ***TP53* Disruptive Mutations Lead to Head and Neck Cancer Treatment Failure through Inhibition of Radiation-Induced Senescence**

Heath D. Skinner, Vlad C. Sandulache, Thomas J. Ow, Raymond E. Meyn, John S. Yordy, Beth M. Beadle, Alison L. Fitzgerald, Uma Giri, K. Kian Ang, and Jeffrey N. Myers

301 **Prognostic Significance of Plasma Osteopontin in Patients with Locoregionally Advanced Head and Neck Squamous Cell Carcinoma Treated on TROG 02.02 Phase III Trial**

Annette M. Lim, Danny Rischin, Richard Fisher, Hongbin Cao, Kathleen Kwok, Daniel Truong, Grant A. McArthur, Richard J. Young, Amato Giaccia, Lester Peters, and Quynh-Thu Le

308 ***NKX3.1* Haploinsufficiency Is Prognostic for Prostate Cancer Relapse following Surgery or Image-Guided Radiotherapy**

Jennifer A. Locke, Gaetano Zafarana, Adrian S. Ishkanian, Michael Milosevic, John Thoms, Cherry L. Have, Chad A. Malloff, Wan L. Lam, Jeremy A. Squire, Melania Pintilie, Jenna Sykes, Varune Rohan Ramnarine, Alice Meng, Omer Ahmed, Igor Jurisica, Theo van der Kwast, and Robert G. Bristow

LETTER TO THE EDITOR

317 **A CDD Polymorphism as Predictor of Capecitabine-Induced Hand–Foot Syndrome—Letter**

Joseph Ciccolini, Alexandre Evrard, and Bruno Lacarelle


CORRECTIONS

318 **Correction: Lysosomal Sequestration of Sunitinib: A Novel Mechanism of Drug Resistance**

319 **Correction: *ABCB1* (*MDR1*) Polymorphisms and Progression-Free Survival among Women with Ovarian Cancer following Paclitaxel/Carboplatin Chemotherapy**

ABOUT THE COVER

B7H3 represents a novel driver of gliomagenesis by mediating an immunosuppressive and proinvasive phenotype in glioblastoma. Immunofluorescence demonstrates the perivascularly (alpha-SMA staining; red) enhanced expression of B7H3 (vesicular distribution; green) in human glioblastoma tissue (nuclei staining; blue). For details, see the article by Lemke and colleagues on page 105 of this issue.



Clinical Cancer Research

18 (1)

Clin Cancer Res 2012;18:1-320.

Updated version Access the most recent version of this article at:
<http://clincancerres.aacrjournals.org/content/18/1>

E-mail alerts [Sign up to receive free email-alerts](#) related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, use this link <http://clincancerres.aacrjournals.org/content/18/1>. Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.